In vitro biological activity of some new 1,2,4-triazole derivatives with their potentiometric titrations

Gursoy-Kol, Ozlem/0000-0003-2637-9023WOS: 000401783500006In this study, 3-alkyl(aryl)-4-amino-4,5-dihydro-1H-1,2,4-triazol-5-ones 3 have been reacted with 4-methoxy-3-(p-toluenesulfonyloxy)-benzaldehyde 1 to afford the corresponding nine new 3-alkykary1)-4-[4-methoxy-3-(p-toluenesulfonyloxy)benzylidenamino)-4,5-dihydro-1H-1,2,4-triazol-5-ones 4. Then, the acetylation reactions of compounds 4 have been investigated and 5 type compounds have been obtained. the structures of fifteen new compounds have been characterized by IR, H-1 and C-13 NMR, MS and UV-Vis spectral data. the synthesized compounds have been analyzed for their in vitro potential antioxidant activities by three different methods. Those antioxidant activities have been compared to standard antioxidants such as BHA, BHT and a-tocopherol. Compounds 4b, 4d and 5d show best activity for iron binding. in addition, the compounds 4 have been titrated potentiometrically with tetrabutylammonium hydroxide (TBAH) in four non-aqueous solvents. Furthermore, these fifteen new compounds have been screened for their antimicrobial activities.Scientific Research Projects Coordination Unit of Kafkas UniversityKafkas University [2011-14EF-32]This work was supported by the Scientific Research Projects Coordination Unit of Kafkas University (Project Number: 2011-14EF-32). the authors thank Dr. Z. Ocak for the determination of pKa values and Dr. M. Calapoglu for antioxidant activities

In Vitro Antioxidant and Antimicrobial Properties of Some New 4,5-Dihydro-1H-1,2,4-triazole-5-ones

Gursoy-Kol, Ozlem/0000-0003-2637-9023; Alpay Karaoglu, Sengul/0000-0003-1047-8350WOS: 000452028200012In this study, 3-alkyl(aryl)-4-amino-4,5-dihydro-1H-1,2,4-triazol-5-ones (3a-3h) reacted with 3-benzenesulfonyloxy-4-methoxybenzaldehyde (1a-1h) to afford eight new 3-alkyl(aryl)-4-(3-benzenesulfonyloxy-4-methoxybenzylidenamino)-4,5-dihydro-1H-1,2,4-triazol-5-ones (4a-4h). Then, the acetylation reactions of compounds 4a-e and 4g were investigated and compounds 5 were obtained, respectively. the structures of fourteen new compounds were characterized by elemental analysis, IR H-1 nuclear magnetic resonance (NMR), C-13 NMR, mass spectrometry, and ultraviolet spectral data. the synthesized compounds were analyzed for their in vitro potential antioxidant activities in three different methods. Compounds 4d, 4e, and 5g showed the best activity for iron binding. in addition, the compounds 4a-4h were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents. Furthermore, these 14 new compounds and 14 recently reported 3-alkyl(ary1)-4-(4-benzenesulfonyloxybenzylidenarnino)-4,5-dihydro-1H-1,2,4-triazol-5-ones (6a, 6b, 6d, 6e, and 6g-6i) and 1-acetyl-3-alkyl(aryl)-4-(4-benzenesulfonyloxybenzylide 4,5-dihydro-1H-1,2,4-triazol-5-ones (7a, 7b, 7d, 7e and 7g-7i) were screened for their antimicrobial activities. [GRAPHICS] .Scientific Research Projects Coordination Unit of Kafkas UniversityKafkas University [2011-FEF-32]Financial support provided by the Scientific Research Projects Coordination Unit of Kafkas University (Project Number: 2011-FEF-32) is gratefully acknowledged. the authors also thank Dr. Zafer Ocak for the determination of pKa values and Dr. Mustafa Calapoglu for antioxidant activities

L-tyrosine and L-tryptophan

In this report, a novel voltammetric sensor based on polyoxometalate (H3PW12040, POM) functionalized reduced graphene oxide (rGO) modified glassy carbon electrode (GCE) was presented for simultaneous determination of L-tyrosine (L-Tyr) and L-tryptophan (L-Trp). The nanocomposites were characterized by transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV). The electrochemical determination of L-Tyr and L-Trp has been studied using square wave voltammetry (SWV) on GCE modified with POM-rGO composite (POM-rGOIGCE). The developed method was also applied successfully for the simultaneous determination of L-Tyr and L-Trp in spiked serum sample and the linearity range of L-Tyr and L-Trp was 1.0 x 10(-11) - 1.0 x 10(-9)M with the detection limit of 2.0 x 10(-12)M. (C) 2016 Elsevier B.V. All rights reserved

Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience

Background: Febrile neutropenia (FN) is generally a complication of cancer chemotherapy in patients with hematological malignancies. Objective: To evaluate the febrile neutropenia episodes of hematological patients and their outcomes with respect to fungal pathogens, primary antifungal prophylaxis antifungal therapy. Methods: All consecutive patients older than 14 years of age and who developed febrile neutropenia episodes from September 2010 to November 2011 were incorporated into this study. Results: In total, we retrospectively evaluated 86 consecutive patients and their 148 neutropenic episodes. Of the 86 patients, 45 were male and the mean age was 47,65±15,06 years (range: 17–82 years). The mean MASCC score was 18,72 ± 9,43. Systemic antifungal drug was initiated to 17 patients with probable fungal infection and 12 patients with possible fungal infection. Of seven patients who received posaconazole prophylaxis, five were treated with systemic fungal infection due to possible fungal infection. Conclusions:It is obvious that more studies focused on primary prophylaxis are needed and primary or secondary antifungal prophylaxis should be evaluated in terms of provided benefits and disadvantages. Timely and appropriately initiated antifungal treatment is one of the most important factors for a good prognosis for recovery from a neutropenic phase

Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience

Background: Febrile neutropenia (FN) is generally a complication of cancer chemotherapy in patients with hematological malignancies.Objective: To evaluate the febrile neutropenia episodes of hematological patients and their outcomes with respect to fungal pathogens, primary antifungal prophylaxis antifungal therapy.Methods: All consecutive patients older than 14 years of age and who developed febrile neutropenia episodes from September 2010 to November 2011 were incorporated into this study.Results: In total, we retrospectively evaluated 86 consecutive patients and their 148 neutropenic episodes. Of the 86 patients, 45 were male and the mean age was 47,65±15,06 years (range: 17–82 years). The mean MASCC score was 18,72 ± 9,43. Systemic antifungal drug was initiated to 17 patients with probable fungal infection and 12 patients with possible fungal infection. Of seven patients who received posaconazole prophylaxis, five were treated with systemic fungal infection due to possible fungal infection.Conclusions: It is obvious that more studies focused on primary prophylaxis are needed and primary or secondary antifungal prophylaxis should be evaluated in terms of provided benefits and disadvantages. Timely and appropriately initiated antifungal treatment is one of the most important factors for a good prognosis for recovery from a neutropenic phase.Key words: Hematological patients, febrile neutropenia, antifungal prophylaxis, antifungal treatmen

The outcome of non-carbapenem-based empirical antibacterial therapy and VRE colonisation in patients with hematological malignancies

Background: Febrile neutropenia (FN) is generally a complication of cancer chemotherapy. Objective: We retrospectively evaluated the febrile neutropenia episodes and their outcomes with respect to modification rates of non-carbapenem-based empirical antibacterial therapy and vancomycin-resistant enterococcus (VRE) colonisation that caused to VRE bacteremia in patients with hematological malignancies. Methods: All consecutive patients, who were older than 14 years of age and developed febrile neutropenia episodes due to hematological malignancies from September 2010 to November 2011 at the hematology department were included into the study. Results: In total, 86 consecutive neutropenic patients and their 151 febrile episodes were evaluated. The mean MASCC prognostic index score was 18,72 ± 9,43. Among 86 patients, 28 patients experienced a total of 30 bacteremia episodes of bacterial origin. Modification rates of both, empirical monotherapy and combination therapies, were found similar, statistically (P =0,840). Conclusion: Our results suggest that initiating of non-carbapenem based therapy does not provide high response rates in the treatment of febrile neutropenia attacks. Furthermore, non-carbapenem-based empirical therapy provides benefit in regard to cost-effectiveness and antimicrobial stewardship when local antibiotic resistance patterns of gram-negative bacteria are considered. Patients who are colonized with VRE are more likely to develop bacteremia with VRE strains as a result of invasive procedures and severe damage of mucosal barriers observed in this group of patients

Nanohybrid for Electrocatalytic Oxidation of Methanol

Fuel cells have important applications in recent decades due to high-energy demands, fossil fuel depletions, and environmental pollution throughout world. Pt/Pd nanoparticles/polyoxometalate/ionic liquid (ILs) nanohybrid synthesized for the first time and characterized by transmission electron microscope, scanning electron microscope, X-ray photo electron spectroscopy, energy-dispersive X-ray spectroscopy and X-ray diffraction method. A cost-effective catalyst has been developed on Pt/Pd nanoparticles/polyoxometalate/ionic liquid nanohybrid. The developed catalyst based on bimetallic nanoparticle demonstrates effective methanol oxidation in comparison with catalysts on monometallic nanoparticle and polyoxometalate/ionic liquid nanohybrid. (C) 2018 The Electrochemical Society